日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Impact of Disease Burden of Patients with Psoriasis on Biologic Therapy Switching: Real-World Evidence from the CorEvitas Psoriasis Registry

银屑病患者疾病负担对生物制剂治疗转换的影响:来自CorEvitas银屑病注册研究的真实世界证据

Blauvelt, Andrew; McLean, Robert R; Beaty, Silky W; Sima, Adam P; Low, Robert; Stark, Jeffrey L; McClung, Laura; Bagel, Jerry

Real-World Use and Effectiveness Outcomes in Patients with Rheumatoid Arthritis Treated with Upadacitinib: An Analysis from the CorEvitas Registry

Upadacitinib治疗类风湿性关节炎患者的真实世界应用及疗效结果:来自CorEvitas注册研究的分析

Baker, Joshua F; Zueger, Patrick; Ali, Mira; Bennett, Denise; Yu, Miao; Munoz Maldonado, Yolanda; McLean, Robert R

Prevalence and Factors Associated With Patient-Clinician Discordance Among Patients With Rheumatoid Arthritis Initiating Advanced Therapy

类风湿性关节炎患者开始接受高级治疗时,患者与临床医生意见不一致的发生率及相关因素

Curtis, Jeffrey R; McLean, Robert R; Lee, I-Heng; Mackey, Rachel H; Moore, Page C; Haubrich, Richard; Greenberg, Jeffrey D; Wu, Alicea

Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

古塞库单抗治疗六个月后,活动性银屑病关节炎患者报告结局的改善:来自CorEvitas银屑病关节炎/脊柱关节炎注册研究的真实世界数据

Mease, Philip J; Ogdie, Alexis; Tesser, John; Shiff, Natalie J; Zhao, Ruizhi Sophia; Chakravarty, Soumya D; Kelleman, Michael; Dodge, Rhiannon; McLean, Robert R; Broadwell, Aaron; Kavanaugh, Arthur; Merola, Joseph F

History of diabetes is associated with reduced likelihood of achieving PASI75 and PASI90 at 12 months among psoriasis patients treated with biologics: A prospective analysis in the CorEvitas Psoriasis Registry

既往糖尿病史与接受生物制剂治疗的银屑病患者在12个月时达到PASI75和PASI90的可能性降低相关:CorEvitas银屑病注册研究的前瞻性分析

Enos, Clinton W; Maldonado, Yolanda Munoz; Kang, Hyung-Joo; McLean, Robert R; Van Voorhees, Abby S

Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry

对大型真实世界特应性皮炎患者队列的疾病负担、治疗和合并症进行特征分析:CorEvitas 特应性皮炎注册研究

Silverberg, Jonathan I; Cronin, Angel; Jones, Eric A; Dave, Swapna S; McLean, Robert R; Greenberg, Jeffrey; Strober, Bruce; Bieber, Thomas; Gooderham, Melinda; Paller, Amy S; Simpson, Eric L

Skin Clearance is Associated with Reduced Treatment Failure in Patients with Psoriasis: Real-World Evidence from the CorEvitas Psoriasis Registry

皮肤清除率与银屑病患者治疗失败率降低相关:来自CorEvitas银屑病注册研究的真实世界证据

McLean, Robert R; Sima, Adam P; Beaty, Silky; Low, Robert; Spitzer, Rebecca L; Stark, Jeffrey L; Lesser, Elizabeth; Lee, Edward; Armstrong, April

Durability of Near-Complete Skin Clearance in Patients with Psoriasis Using Systemic Biologic Therapies: Real-World Evidence from the CorEvitas Psoriasis Registry

使用系统性生物制剂治疗银屑病患者,其皮肤近乎完全清除的持久性:来自CorEvitas银屑病注册研究的真实世界证据

McLean, Robert R; Sima, Adam P; Beaty, Silky; Jones, Eric A; Eckmann, Thomas; Low, Robert; McClung, Laura; Spitzer, Rebecca L; Stark, Jeffrey; Armstrong, April

Racial and Ethnic Differences in Sociodemographic, Clinical, and Treatment Characteristics Among Patients with Atopic Dermatitis in the United States and Canada: Real-World Data from the CorEvitas Atopic Dermatitis Registry

美国和加拿大特应性皮炎患者的社会人口学、临床和治疗特征的种族和民族差异:来自CorEvitas特应性皮炎注册研究的真实世界数据

Silverberg, Jonathan I; Shi, Vivian Y; Alexis, Andrew; Pierce, Evangeline; Cronin, Angel; McLean, Robert R; Roberts-Toler, Carla; Rueda, Maria J; Atwater, Amber R; Simpson, Eric

Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry

来自 CorEvitas 银屑病注册研究的亚洲成年银屑病患者与非西班牙裔白人成年银屑病患者使用生物制剂的疗效比较

Yu, Chen; Wang, Gang; Burge, Russel T; Ye, Erjia; Dou, Guanshen; Li, Jinnan; Harrison, Ryan W; McLean, Robert R; Kerti, Samantha J; Bagel, Jerry